Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.45 |
| ▸ | LTA4H | P09960 | 11/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20255353 | 1.00 | ALDH1A1 (0.47) | ALDH1A1PDCD1CD274LTA4HRAB9A | |
| SCHEMBL18291479 | 0.92 | ALDH1A1 (0.58) | ALDH1A1LTA4HCCR5 | |
| SCHEMBL20037663 | 0.92 | ALDH1A1 (0.58) | ALDH1A1LTA4HCCR5 | |
| SCHEMBL20037672 | 0.92 | ALDH1A1 (0.58) | ALDH1A1LTA4HCCR5 | |
| SCHEMBL18291538 | 0.91 | RAB9A (0.52) | ALDH1A1PDCD1CD274LTA4HRAB9A | |
| SCHEMBL20037754 | 0.88 | PDCD1 (0.41) | ALDH1A1PDCD1CD274LTA4HRAB9A | |
| SCHEMBL20037952 | 0.84 | HRH3 (0.48) | LTA4HKMT2A | |
| SCHEMBL16193062 | 0.84 | HRH3 (0.48) | LTA4HKMT2A | |
| SCHEMBL2234417 | 0.82 | ALDH1A1 (0.47) | ALDH1A1PDCD1CD274LTA4HRAB9A | |
| SCHEMBL5045179 | 0.82 | KMT2A (0.55) | ALDH1A1PDCD1CD274LTA4HMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | ALDH1A1 944/4885PDCD1 344/4885CD274 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.